These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 34870794)
21. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma. Fukuoka M; Taki J; Mochizuki T; Kinuya S Clin Nucl Med; 2011 Jan; 36(1):1-7. PubMed ID: 21157198 [TBL] [Abstract][Full Text] [Related]
22. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre. Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727 [TBL] [Abstract][Full Text] [Related]
23. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma. Carrasquillo JA; Pandit-Taskar N; Chen CC Semin Nucl Med; 2016 May; 46(3):203-14. PubMed ID: 27067501 [TBL] [Abstract][Full Text] [Related]
24. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196 [TBL] [Abstract][Full Text] [Related]
25. High-Specific-Activity- Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867 [TBL] [Abstract][Full Text] [Related]
26. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341 [TBL] [Abstract][Full Text] [Related]
28. Use of 131I-MIBG scintigraphy in the evaluation of suspected pheochromocytoma. Swensen SJ; Brown ML; Sheps SG; Sizemore GW; Gharib H; Grant CS; van Heerden JA Mayo Clin Proc; 1985 May; 60(5):299-304. PubMed ID: 3990377 [TBL] [Abstract][Full Text] [Related]
29. Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Wakabayashi H; Taki J; Inaki A; Nakamura A; Kayano D; Fukuoka M; Matsuo S; Nakajima K; Kinuya S Ann Nucl Med; 2013 Nov; 27(9):839-46. PubMed ID: 23864328 [TBL] [Abstract][Full Text] [Related]
30. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990 [TBL] [Abstract][Full Text] [Related]
32. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242 [TBL] [Abstract][Full Text] [Related]
33. [Therapeutic effectiveness of 131I-MIBG on malignant pheochromocytoma--results of long-term follow-up]. Kusakabe K; Kanaya K; Kanaya S; Yazaki E; Nakano K; Matsumoto N; Kobayashi H; Maki M; Itou Y; Obara T Kaku Igaku; 1994 Dec; 31(12):1495-502. PubMed ID: 7861648 [TBL] [Abstract][Full Text] [Related]
34. 131I-MIBG--a new agent in diagnosis and treatment of pheochromocytoma. Shapiro B; Sisson JC; Eyre P; Copp JE; Dmuchowski C; Beierwaltes WH Cardiology; 1985; 72 Suppl 1():137-42. PubMed ID: 4053121 [TBL] [Abstract][Full Text] [Related]
35. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695 [TBL] [Abstract][Full Text] [Related]
36. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. van Hulsteijn LT; Niemeijer ND; Dekkers OM; Corssmit EP Clin Endocrinol (Oxf); 2014 Apr; 80(4):487-501. PubMed ID: 24118038 [TBL] [Abstract][Full Text] [Related]
37. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Porzig A; Matthay KK; Dubois S; Pampaloni M; Damon L; Hawkins R; Goldsby R; Hollinger F; Fitzgerald P Horm Metab Res; 2012 Jun; 44(7):539-42. PubMed ID: 22588707 [TBL] [Abstract][Full Text] [Related]
38. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728 [TBL] [Abstract][Full Text] [Related]
39. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Al-Ward R; Brondani VB; Sawani S; Potter CL; Xu G; Waguespack SG; Varghese J; Habra MA; Lu Y; Jimenez C Clin Nucl Med; 2024 Jul; 49(7):610-620. PubMed ID: 38630996 [TBL] [Abstract][Full Text] [Related]
40. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]